Onset of Musculoskeletal Adverse Events Varies Between Statins
MONDAY, Nov. 19, 2018 -- The onset of musculoskeletal adverse events (MAEs) during statin monotherapy is significantly faster with use of atorvastatin and rosuvastatin versus simvastatin, according to a study published online Nov. 7 in Pharmacology... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 19, 2018 Category: Pharmaceuticals Source Type: news
New Studies Give Mixed Results About Taking Fish Oil and Vitamin D
(CHICAGO) — Taking fish oil or vitamin D? Big studies give long-awaited answers on who does and does not benefit from these popular nutrients.
Fish oil taken by healthy people, at a dose found in many supplements, showed no clear ability to lower heart or cancer risks. Same for vitamin D.
But higher amounts of a purified, prescription fish oil slashed heart problems and heart-related deaths among people with high triglycerides, a type of fat in the blood, and other risks for heart disease. Doctors cheered the results and said they could suggest a new treatment option for hundreds of thousands of patients like these.
...
Source: TIME: Health - November 10, 2018 Category: Consumer Health News Authors: MARILYNN MARCHIONE / AP Tags: Uncategorized onetime Supplements Source Type: news
Australian watchdog's appeal against Pfizer ruling dismissed by court
Australia's competition watchdog said on Friday the High Court dismissed its special leave application to appeal a court's decision on whether Pfizer Inc's local unit used its market power to limit competition for its cholesterol-lowering drug Lipitor. (Source: Reuters: Health)
Source: Reuters: Health - October 19, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Court dismisses Australian watchdog's appeal against Pfizer ruling
Australia's competition watchdog said on Friday the High Court dismissed its special leave application to appeal a court's decision on whether Pfizer Inc's local unit used its market power to limit competition for its cholesterol-lowering drug Lipitor. (Source: Reuters: Health)
Source: Reuters: Health - October 19, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Statins: Any Benefit in Knee OA?
(MedPage Today) -- Only after 5 years of use, and with atorvastatin (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 30, 2018 Category: Primary Care Source Type: news
Atorvastatin Calcium Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - August 2, 2018 Category: Drugs & Pharmacology Source Type: news
Can a Statin Treat Chronic Subdural Hematoma? (CME/CE)
(MedPage Today) -- Chinese trial shows atorvastatin decreased volume, improved neurologic function (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - July 30, 2018 Category: Neurology Source Type: news
Rhabdomyolysis and AKI Following Atorvastatin-Gemfibrozil Rhabdomyolysis and AKI Following Atorvastatin-Gemfibrozil
This case report demonstrates that severe rhabdomyolysis due to statins with or without fibrates may occur with few clinical symptoms and signs, even many weeks after discontinuation of therapy.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 4, 2018 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Australian watchdog appeals to high court on Pfizer's alleged abuse of market power
MELBOURNE (Reuters) - Australia's competition watchdog said on Monday it would appeal to the nation's high court for a ruling on whether Pfizer Inc used its market power to limit competition for its cholesterol-lowering drug Lipitor. (Source: Reuters: Health)
Source: Reuters: Health - June 25, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Australian anti-trust watchdog loses appeal against Pfizer over Lipitor sales
MELBOURNE (Reuters) - An Australian court dismissed an appeal by the nation's anti-trust watchdog in a case against Pfizer Inc in which the regulator alleged the company had used its market power to limit competition for its cholesterol-lowering drug Lipitor. (Source: Reuters: Health)
Source: Reuters: Health - May 25, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Gene study spots clues to heart risk for statin patients
(Vanderbilt University Medical Center) A Vanderbilt-led research team has discovered genetic variations that increase the risk of heart attack even when patients are receiving a statin drug like Lipitor or Crestor to lower their blood cholesterol. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 9, 2018 Category: International Medicine & Public Health Source Type: news
SECURE-PCI:'Statin Loading' in ACS Doesn't Cut 30-Day Event Risk SECURE-PCI:'Statin Loading' in ACS Doesn't Cut 30-Day Event Risk
But 30-day events dropped significantly after two big atorvastatin doses in one predefined subgroup of the trial ' s broad acute coronary syndrome population, a secondary but enticing result.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 12, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news
This Cholesterol Drug Combination Might Lower Your Risk of Death, Study Finds
(ORLANDO) — A newer cholesterol drug, used with older statin medicines, modestly lowered heart risks and deaths in a big study of heart attack survivors that might persuade insurers to cover the pricey treatment more often.
Results on the drug, Praluent, were announced Saturday at an American College of Cardiology conference in Florida. It’s the first time a cholesterol-lowering drug has reduced deaths since statins such as Lipitor and Crestor came out decades ago.
“It’s the ultimate outcome; it’s what matters to patients,” said study leader Dr. Philippe Gabriel Steg of Hospital Bichat i...
Source: TIME: Health - March 10, 2018 Category: Consumer Health News Authors: Marilyn Marchione / AP Tags: Uncategorized APH healthytime medicine onetime Source Type: news
Introduction of generic version reduces atorvastatin expenditure
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news
Dr Reddy's recalls 80,000+ bottles of Atorvastatin from US
The product is being recalled through three separate letters to the drug regulator. Dr Reddy's officials were not immediately available for comment. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 8, 2018 Category: Pharmaceuticals Source Type: news
